Stiripentol in Dravet Syndrome

Mayo Clinic

Status

Conditions: Dravet Syndrome

Treatments: Drug: stiripentol

Study type: Expanded Access

Funder types: Other

Identifiers

NCT01533506

12-000690

Details and patient eligibility

About

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Sex: Female

Ages: 11+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures